Syntis Bio launches first patient dosing for groundbreaking oral obesity therapy
SYNT-101 is a once-daily oral pill engineered to redirect nutrient absorption beyond the small intestine’s duodenum
SYNT-101 is a once-daily oral pill engineered to redirect nutrient absorption beyond the small intestine’s duodenum
It is also approved for?AIDS-related Kaposi sarcoma?after failure of highly active antiretroviral therapy, as well as for HIV-negative adult patients with Kaposi sarcoma
Moderna will appeal to the Federal Circuit to assert that its government-contractor immunity limits liability under federal law
A next-generation, cell-based immunotherapy, CAR-T therapy engineers a patient’s own immune cells to detect and destroy cancer
The company has shown remarkable growth, posting a three-year CAGR of around 75% with an ARR of roughly Rs 100 crore and impressive gross margins
Merck emphasized the broader significance of the findings
This study evaluated a difficult-to-treat Crohn's disease patient population
Subscribe To Our Newsletter & Stay Updated